Popular Trials
Mu-opioid Receptor Agonist
Eluxadoline for Irritable Bowel Syndrome
This trial is testing a medication to help manage IBS-D symptoms in children. The goal is to see how well it works, how the body processes it, and if it is safe for kids. The study focuses on children because they need effective treatments for IBS-D. The medication is taken orally and is designed to treat diarrhoea-predominant irritable bowel syndrome.
Popular Filters
Trials for IBS Patients
Behavioural Intervention
Fecal Microbiota Transplantation for Depression
This trial is testing whether a treatment called Fecal Microbiota Transplantation (FMT) is effective, safe, and tolerable for adults with Major Depressive Disorder (MDD) who also have Inflammatory Bowel Syndrome (IBS). The study will also look at whether FMT affects cognitive and neural changes associated with MDD and MDD+IBS.
Behavioural Intervention
Mindfulness Training for Irritable Bowel Syndrome
This trial will compare the effectiveness of two different mindfulness-based interventions (MBIs) for treating irritable bowel syndrome (IBS), with a control group who will receive stress management training. The trial will use both clinician and patient assessed measures of IBS symptoms, as well asEcological Momentary Assessment to assess stress and symptoms in daily life.
Mu-opioid Receptor Agonist
Eluxadoline for Pediatric IBS-D
This trial will check the safety of a medication called Eluxadoline for children with IBS-D who have already taken part in earlier studies. The medication helps to reduce diarrhea and stomach pain by slowing down bowel movements. Eluxadoline is a new drug approved for managing diarrhea predominant irritable bowel syndrome (IBS-D).
Phase 3 Trials
Behavioural Intervention
Fecal Microbiota Transplantation for Depression
This trial is testing whether a treatment called Fecal Microbiota Transplantation (FMT) is effective, safe, and tolerable for adults with Major Depressive Disorder (MDD) who also have Inflammatory Bowel Syndrome (IBS). The study will also look at whether FMT affects cognitive and neural changes associated with MDD and MDD+IBS.
Mu-opioid Receptor Agonist
Eluxadoline for Pediatric IBS-D
This trial will check the safety of a medication called Eluxadoline for children with IBS-D who have already taken part in earlier studies. The medication helps to reduce diarrhea and stomach pain by slowing down bowel movements. Eluxadoline is a new drug approved for managing diarrhea predominant irritable bowel syndrome (IBS-D).
Behavioural Intervention
TEA + Lexapro for Irritable Bowel Syndrome
This trial tests TEA and escitalopram on people with IBS-C to see if they can reduce abdominal pain. TEA uses electrical currents on the skin, and escitalopram boosts serotonin in the brain.
Guanylate Cyclase-C Agonist
Long-Term Safety of Linaclotide for Constipation
This trial tests linaclotide, a medication that helps relieve constipation by increasing fluid in the intestines, in children aged 6-17 with constipation issues. Linaclotide is approved for treating certain types of constipation.
Trials With No Placebo
Behavioural Intervention
Fecal Microbiota Transplantation for Depression
This trial is testing whether a treatment called Fecal Microbiota Transplantation (FMT) is effective, safe, and tolerable for adults with Major Depressive Disorder (MDD) who also have Inflammatory Bowel Syndrome (IBS). The study will also look at whether FMT affects cognitive and neural changes associated with MDD and MDD+IBS.
Behavioural Intervention
Mindfulness Training for Irritable Bowel Syndrome
This trial will compare the effectiveness of two different mindfulness-based interventions (MBIs) for treating irritable bowel syndrome (IBS), with a control group who will receive stress management training. The trial will use both clinician and patient assessed measures of IBS symptoms, as well asEcological Momentary Assessment to assess stress and symptoms in daily life.
Mu-opioid Receptor Agonist
Eluxadoline for Pediatric IBS-D
This trial will check the safety of a medication called Eluxadoline for children with IBS-D who have already taken part in earlier studies. The medication helps to reduce diarrhea and stomach pain by slowing down bowel movements. Eluxadoline is a new drug approved for managing diarrhea predominant irritable bowel syndrome (IBS-D).
Non-invasive Brain Stimulation
Brain Stimulation for Gastrointestinal Disorders
This trial is testing a non-invasive brain stimulation technique called rTMS on healthy people and those with IBS or FD. The goal is to see if it can help regulate automatic body functions like digestion and heart rate by changing brain activity. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that has been used to treat various neurological and psychiatric conditions, including major depression, migraine-associated headaches, and obsessive-compulsive disorder.
View More Related Trials
Frequently Asked Questions
Introduction to ibs
What are the top hospitals conducting ibs research?
Living with irritable bowel syndrome (IBS) can be a challenging and frustrating experience, but there is hope in the form of ongoing clinical trials conducted by top hospitals. At the University of Michigan in Ann Arbor, researchers are currently running six active IBS trials, building upon their impressive history of 13 previous studies since their first recorded trial back in 2007. Meanwhile, at Valencia Medical and Research Center in Miami, specialists are conducting three active IBS trials as part of their continuous efforts to understand and find effective treatments for this condition. Although they may have fewer overall trials to their name compared to other institutions on this list, Valencia's commitment began more recently with their first recorded IBS trial taking place in 2017.
In San Antonio, the Sun Research Institute is also making strides with three ongoing IBS trials and an additional eight completed studies since embarking on its journey into IBS research back in 2006. Closer to the west coast lies UCLA in Los Angeles where researchers are engaged in two active clinical trials focusing specifically on IBS; these endeavors mark significant milestones for UCLA as they only began exploring this area through formalized research projects starting from 2017.
Even further northward stands Canadian Phase Onward Inc., situated amidst Toronto's medical community. While hosting two current clinical tests aimed towards treating patients affected by IBS-related symptoms,this establishment has actively contributed over time through participation within four comprehensive experiments initiated from early days leading all way up until year-ago period duringwhen it started venturing into aforementioned territory backin 2005.
These dedicated hospitals represent beacons of progress and innovation when it comes to understanding and finding solutions for those living with debilitating conditions like IBS. Their combined efforts showcase how every step taken towards unraveling the complexities surrounding this syndrome brings us closer not only to better treatment options but also a clearer path forward toward improved quality of life for millions worldwide
Which are the best cities for ibs clinical trials?
When it comes to clinical trials for irritable bowel syndrome (IBS), several cities have emerged as leading hubs of research and innovation. Miami, Florida takes the top spot with 21 active trials investigating treatments like Eluxadoline, Linaclotide 145 μg (for IBS-C participants), and 72 μg linaclotide. Following closely behind is Houston, Texas with 11 ongoing studies focusing on interventions such as 72 μg linaclotide and Eluxadoline. Atlanta, Georgia also demonstrates promising research activity in this field with 10 active trials studying various treatment options including Eluxadoline and Linaclotide 145 μg (for IBS-C participants). These cities provide individuals living with IBS an opportunity to participate in cutting-edge clinical trials that may pave the way for improved management strategies and enhanced quality of life.
Which are the top treatments for ibs being explored in clinical trials?
Clinical trials are actively exploring promising treatments for irritable bowel syndrome (IBS). Rifaximin, a well-established option, is being tested in two ongoing trials. Since its introduction in 2007, it has been involved in a total of 12 IBS clinical trials. Another avenue being explored is Diet A, currently undergoing one active trial and marking its first listing this year. Additionally, research is focusing on the benefits of a diet low in all FODMAP groups, with one ongoing trial dedicated to investigating its potential as an IBS treatment since 2023. These innovative approaches offer hope for individuals living with the challenges posed by IBS and may pave the way for improved management strategies moving forward.
What are the most recent clinical trials for ibs?
Recent clinical trials offer promising advancements in the treatment of irritable bowel syndrome (IBS). Notably, a Phase 2 trial explored the benefits of donor fecal microbiota transplantation (FMT) as a potential therapy for IBS. Additionally, Phase 3 trials investigated the efficacy of tenapanor and tenpanor 50 mg BID in managing IBS symptoms. Another study evaluated the use of TEA to alleviate symptoms associated with IBS. These ongoing trials aim to expand our understanding and provide new avenues for effective management of this challenging condition.
What ibs clinical trials were recently completed?
Several recent clinical trials have made significant strides in the field of irritable bowel syndrome (IBS) research. In December 2021, Michael Camilleri, MD successfully completed a trial investigating the potential benefits of Aldafermin for IBS patients. Additionally, Cedars-Sinai Medical Center completed a trial in November 2020 studying Rifaximin as a potential treatment option for IBS. Last but not least, Beth Israel Deaconess Medical Center wrapped up their DS-01 trial in October 2020, further contributing to our understanding of effective treatments for IBS. These advancements highlight the ongoing efforts by researchers to develop better therapies and improve the quality of life for individuals with IBS.